首页> 外国专利> Use of agomelatine, to obtain a drug to treat Smith Magenis syndrome, major depression, seasonal depression, sleep disorder, cardiovascular disease, digestive system disorder, insomnia, shiftlag, appetite disorders and obesity

Use of agomelatine, to obtain a drug to treat Smith Magenis syndrome, major depression, seasonal depression, sleep disorder, cardiovascular disease, digestive system disorder, insomnia, shiftlag, appetite disorders and obesity

机译:使用阿戈美拉汀,以获得治疗史密斯·马格尼斯综合征,重度抑郁症,季节性抑郁症,睡眠障碍,心血管疾病,消化系统疾病,失眠,移位,食欲障碍和肥胖症的药物

摘要

Use of agomelatine (I) or its hydrates, crystalline forms and acid or base addition salts, to obtain a drug to treat Smith Magenis syndrome, is claimed. An independent claim is included for a composition comprising (I) optionally in combination with excipients. ACTIVITY : Antidepressant; Hypnotic; Cardiovascular-Gen.; Anorectic. MECHANISM OF ACTION : 5-Hydroxytryptamine-2C antagonist; Melatoninergic receptor agonist.
机译:要求使用阿戈美拉汀(I)或其水合物,晶体形式和酸或碱加成盐以获得治疗史密斯·马格尼斯综合征的药物。对于包含(I)任选地与赋形剂组合的组合物包括独立权利要求。活性:抗抑郁药;催眠;心血管创厌食的。作用机理:5-羟色胺-2C拮抗剂。黑素能受体激动剂。

著录项

  • 公开/公告号NO338951B1

    专利类型

  • 公开/公告日2016-11-07

    原文格式PDF

  • 申请/专利权人 LES LABORATOIRES SERVIER;

    申请/专利号NO20070005989

  • 发明设计人 MOCAER ELISABETH;FABIANO AGNES;

    申请日2007-11-23

  • 分类号A61K31/165;

  • 国家 NO

  • 入库时间 2022-08-21 14:23:50

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号